. " "@en . . "On the basis of a mass balance study using 14C labeled terfenadine the oral absorption of terfenadine was estimated to be at least 70%"@en . . . . . . . . . . "Terfenadin"@en . "(RS)-1-(4-tert-butylphenyl)-4-{4-[hydroxy(diphenyl)methyl]piperidin-1-yl}-butan-1-ol"@en . "70%"@en . . . . . . . "For the treatment of allergic rhinitis, hay fever, and allergic skin disorders."@en . . "Terfenadine"@en . "Humans and other mammals"@en . "In the U.S., Terfenadine was superseded by fexofenadine in the 1990s due to the risk of cardiac arrhythmia caused by QT interval prolongation."@en . "Mild (e.g., headache, nausea, confusion), but adverse cardiac events including cardiac arrest, ventricular arrhythmias including torsades de pointes and QT prolongation have been reported. LD₅₀=mg/kg (orally in mice)"@en . . . . . . . "Terfenadine"@en . "3.5 hours"@en . . . . . . "50679-08-8"@en . . "Terfenadine competes with histamine for binding at H1-receptor sites in the GI tract, uterus, large blood vessels, and bronchial muscle. This reversible binding of terfenadine to H1-receptors suppresses the formation of edema, flare, and pruritus resulting from histaminic activity. As the drug does not readily cross the blood-brain barrier, CNS depression is minimal."@en . . . . . . "Terfenadina"@en . . . "Terfenadinum"@en . . . "withdrawn"@en . . . . . . . "Timothy G. Fawcett, Christian T. Goralski, David W. Ziettlow, \"Preparation of polymorphically pure terfenadine.\" U.S. Patent US4742175, issued April, 1975."@en . . . . . . . . "Terf\u00E9nadine"@en . .